Citation Impact
Citing Papers
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
2012
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Gastric cancer
2016 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma
2008
Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated withcis-diamminedichloroplatinum(II)
1990
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
2006 Standout
Testicular Germ-Cell Cancer
1997 Standout
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
2004 Standout
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
Nutraceuticals: Facts and fiction
2007 Standout
Cisplatin and hypomagnesemia
1999
National Cancer Data Base report on esophageal carcinoma
1996
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
2008 Standout
Chemoradiotherapy of Locally Advanced Esophageal Cancer
1999 Standout
Comparison of an inflammation‐based prognostic score (GPS) with performance status (ECOG‐ps) in patients receiving palliative chemotherapy for gastroesophageal cancer
2007
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study
1990 StandoutNobel
Natural products: An evolving role in future drug discovery
2011 Standout
Phase II Trial of Docetaxel for Cholangiocarcinoma
1999
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
2001 Standout
Nedaplatin: a cisplatin derivative in cancer chemotherapy
2013
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid—extensive binding to protein and DNA
2003
Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin.
1988 StandoutNobel
Paclitaxel (Taxol)
1995 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Esophageal Cancer
2003 Standout
Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus
1992 Standout
Cisplatin Nephrotoxicity: A Review
2007 Standout
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
1994 Standout
Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus.
1990
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin
1987
Effect of oral administration of arabic gum on cisplatin‐induced nephrotoxicity in rats
2003
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Carboplatin
1989
Toxicity of platinum compounds
2003
p21 in cancer: intricate networks and multiple activities
2009 Standout
Oesophageal carcinoma
2013 Standout
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma
2007
Naringenin attenuates cisplatin nephrotoxicity in rats
2005
Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods
1997
Carboplatin: current status and future prospects
1988
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
1996
Endosonographic features predictive of lymph node metastasis
1994
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: An update including data from the seventh world conference on lung cancer
1995
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
1998
Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
1992
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Paclitaxel and its formulations
2002 Standout
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
1997
Paclitaxel
1994
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
2012 Standout
Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy
1991
Chemotherapy of gastric cancer
1988
Cancer of the Ovary
2004 Standout
Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy
2000
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy
1985
Magnesium in Man: Implications for Health and Disease
2014 Standout
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
2001
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Experience with cisplatin in treatment regimens for esophageal cancer.
1991
Chemotherapy for advanced gastric cancer
2017 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Second neoplasms in acute lymphoblastic leukemia
1983
Effective chemotherapy for esophageal cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II
1981
Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
2007
Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037).
1987
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
New agents in non-small cell lung cancer
1984
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin
1982
Global cancer statistics, 2012
2015 Standout
Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities.
1998
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity
2009
A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma
1996
Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
2001
Cisplatin
1984 Standout
Works of D. P. Kelsen being referenced
Vindesine in the treatment of esophageal carcinoma: a phase II study.
1979
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
2007
Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
1994
Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.
2011
Cisplatin, vindesine, and mitoguazone in the treatment of esophageal cancer.
1986
Phase II trial of PALA in hypernephroma and urinary bladder cancer.
1982
Chemotherapy in esophageal cancer.
1999
Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin.
1985
Multimodality therapy of esophageal cancer: an update.
2000
Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil
2004
Adjuvant therapy of upper gastrointestinal tract cancers.
1991
Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma.
1981
Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer.
1983
Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
1981
Clinical and pathological evaluation of response to chemotherapy in patients with esophageal carcinoma
1983
Phase II trial of PCNU in non-small cell lung cancer.
1983
Phase II study of high-dose cis-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer.
1980
Combined modality therapy in the treatment of esophageal cancer.
1994
Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
1981
Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus.
1985
Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract.
1985
Cisplatin nephrotoxicity
1985
Philadelphia chromosome positive chronic myelogenous leukemia developing in a patient with acute lymphoblastic leukemia
1979